MedTrace Logo

Effect of JointIQ on Joint Discomfort in Healthy Subjects

NCT07382622 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-02-03

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of astragaloside supplementation on joint discomfort in healthy adults. The primary goal is to determine if daily intake of astragaloside can improve knee joint function and reduce discomfort over a 12-week period. Participants will be randomly assigned to receive either an astragaloside capsule or a placebo capsule once daily. Aim to see if those taking astragaloside experience better mobility and fewer joint-related symptoms compared to those in the placebo group.

Conditions

  • Joint Discomfort

Interventions

DIETARY_SUPPLEMENT

Astragaloside

Participants in the Astragaloside Group will receive one astragaloside capsule orally once daily after meals for 12 weeks. The capsule contains the active compound astragaloside, a component of the traditional herb Astragalus. Participants will be asked to continue their usual diet and physical activity levels during the study.

DIETARY_SUPPLEMENT

Maltodextrin (Placebo)

Participants in the Placebo Group will receive one maltodextrin capsule orally once daily after meals for 12 weeks. The capsule is identical in appearance to the astragaloside capsule but contains no active astragaloside. Participants will be asked to continue their usual diet and physical activity levels during the study.

Sponsors & Collaborators

  • Chung Shan Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-24
Primary Completion
2025-10-09
Completion
2025-10-09

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07382622 on ClinicalTrials.gov